Literature DB >> 6386898

Adverse reactions to monoamine oxidase inhibitors. Part I. A comparative study.

J Rabkin, F Quitkin, W Harrison, E Tricamo, P McGrath.   

Abstract

The incidence of major side effects of phenelzine and tranylcypromine is compared with that of imipramine and placebo medication in depressed outpatients. Psychiatric notes in the charts of 198 patients were reviewed. Based on clinical experience and literature review, 14 side effects were selected for study because of serious medical risk or subjective discomfort great enough to require drug discontinuation. Significant differences in risk for major side effects, as well as distinctive side effect profiles for each drug, were found. More side effects occurred on phenelzine, but these tended not to lead to drug discontinuation more often than with tranylcypromine, nor were they accounted for by differences in age, sex, diagnosis, or duration of treatment.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6386898

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  14 in total

Review 1.  The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications.

Authors:  Roger S McIntyre; Ka Young Park; Candy W Y Law; Farah Sultan; Amanda Adams; Maria Teresa Lourenco; Aaron K S Lo; Joanna K Soczynska; Hanna Woldeyohannes; Mohammad Alsuwaidan; Jinju Yoon; Sidney H Kennedy
Journal:  CNS Drugs       Date:  2010-09       Impact factor: 5.749

2.  The role of monoamine oxidase inhibitors in current psychiatric practice.

Authors:  Jess G Fiedorowicz; Karen L Swartz
Journal:  J Psychiatr Pract       Date:  2004-07       Impact factor: 1.325

3.  [Comment about the article "Psychopharmaceuticals and diabetes" of Ress C, Tschoner A, Kaser S, and Ebenbichler CF in Wiener Medizinische Wochenschrift 2011; 161/21-22: 531-42].

Authors:  Sven Ulrich
Journal:  Wien Med Wochenschr       Date:  2012-11-08

Review 4.  Rediscovering monoamine oxidase inhibitors.

Authors:  C Bass; R Kerwin
Journal:  BMJ       Date:  1989-02-11

Review 5.  Treatment of patients with chronic fatigue syndrome.

Authors:  N M Gantz; G P Holmes
Journal:  Drugs       Date:  1989-12       Impact factor: 9.546

6.  Monoamine oxidase inhibitors: clinical review.

Authors:  R A Remick; C Froese
Journal:  Can Fam Physician       Date:  1990-06       Impact factor: 3.275

Review 7.  Gender as a risk factor for adverse events to medications.

Authors:  J C Kando; K A Yonkers; J O Cole
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

Review 8.  Risk-benefit assessment of newer versus older monoamine oxidase (MAO) inhibitors.

Authors:  Y Lecrubier
Journal:  Drug Saf       Date:  1994-04       Impact factor: 5.606

Review 9.  A reassessment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths.

Authors:  Peter Kenneth Gillman
Journal:  J Neural Transm (Vienna)       Date:  2018-09-25       Impact factor: 3.575

10.  Short-acting novel MAO inhibitors: in vitro evidence for the reversibility of MAO inhibition by moclobemide and Ro 16-6491.

Authors:  H H Keller; R Kettler; G Keller; M Da Prada
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-01       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.